This industry could be worth well over $100 billion

A $100 billion opportunity, creating monster opportunity Friday December 10, 2021 | [View On Web]( | [Unsubscribe]( | [Report Spam]( Your TradaVista E-Letter  [This Could be the World’s Next $100 Billion Bull Market](  Psychedelics could be one of the most rewarding opportunities on 2021 – and beyond.  After all, some of these drugs are being found to help treat a range of mental health issues, like obsessive-compulsive disorder, PTSD, addiction, alcoholism, depression, and anxiety.  Johns Hopkins Medicine launched the Center for Psychedelic and Consciousness Research to study compounds like LSD and psilocybin to treat a range of mental health problems, including anorexia, addiction and depression.  New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post.  [Companies are even investigating ketamine-assisted psychotherapy.](  In fact, one company’s 'Ketamine in the Reduction of Alcoholic Relapse' (KARE) psychotherapy intervention study, which was the first controlled study in the world to investigate ketamine-assisted psychotherapy, will be published in the American Journal of Psychiatry later this year.  When and if psychedelics are used more commonly to treat mental health, we could be looking at a $100 billion opportunity, creating monster opportunity.  [Click here to learn more about this opportunity.](  There is a very high degree of risk involved in trading. This email is a paid advertisement. It is for a product or service that is not offered, recommended or endorsed by William Benjamin and neither the company nor its affiliates bear responsibility or control over the content of the advertisement and the product or service offered. Past results are not indicative of future returns. William Benjamin, all individuals and companies affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as advice. It is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. By reading, downloading or otherwise consuming this content your information may be shared with our educational partners. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. To opt out, either [REPLY](mailto:?subject=Unsubscribe%20Request%20-%20{EMAIL}&body=Please%20unsubscribe%20me%2C%20my%20subscription%20email%20is%3A%20{EMAIL}) to this message or click on the link in the footer of this email. 4283 Express Lane, Suite 7621-610, Sarasota, FL 34249 In order to unsubscribe from this mailing list, please click [here](